Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Clomipramine Hydrochloride

FDA-approved product (capsule, oral), marketed as Anafranil, Clomipramine Hydrochloride.

Registered studies
33
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Clomipramine Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Depressive disorder
  • Major depressive disorder
  • Obsessive-compulsive disorder

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Non-selective monoamine reuptake inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA43.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli37.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae18.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis67.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

33registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Clomipramine Hydrochloride in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-5.9 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-5.0 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-5.1 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-5.9 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Clomipramine Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Citalopram vs Clomipramine vs Placebo in Recurrent Depression

    NCT01575158 · start 1997-10

    Registered record
    Registry ID
    NCT01575158
    Conditions
    Depression
    Interventions
    Citalopram; Clomipramine; placebo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    1997-10
    Completion
    2007-09
    Enrolment
    59

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDepression
    InterventionCitalopram; Clomipramine; placebo
    PhaseNot applicable
    Registry statusCompleted

  • To Demonstrate the Relative Bioavailability of Geneva and Basel (Anafranil) 25 mg Clomipramine Hydrochloride Capsules Under Fed and Fasted Conditions

    NCT00913952 · start 1994-04

    Registered record
    Registry ID
    NCT00913952
    Conditions
    Depression
    Interventions
    Geneva 25 mg Clomipramine Hydrochloride Capsules Under Fasting Conditions; Geneva 25 mg Clomipramine Hydrochloride Capsules Under Fed Conditions; Basel (Anafranil) 25 mg Clomipramine Hydrochloride Capsules Under Fed Conditions
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    1994-04
    Completion
    1994-06
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDepression
    InterventionGeneva 25 mg Clomipramine Hydrochloride Capsules Under Fasting Conditions; Geneva 25 mg Clomipramine Hydrochloride Capsules Under Fed Conditions; Basel (Anafranil) 25 mg Clomipramine Hydrochloride Capsules Under Fed Conditions
    PhasePhase 1
    Registry statusCompleted

  • To Demonstrate the Relative Bioavailability of Geneva and Basel (Anafranil) 25 mg Clomipramine Hydrochloride Capsules Under Fasted Conditions

    NCT00913783 · start 1992-11

    Registered record
    Registry ID
    NCT00913783
    Conditions
    Depression
    Interventions
    Clomipramine Hydrochloride 25 mg Capsules (Geneva Pharmaceuticals); Anafranil Clomipramine Hydrochloride 25 mg Capsules (Basel)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    1992-11
    Completion
    1992-12
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDepression
    InterventionClomipramine Hydrochloride 25 mg Capsules (Geneva Pharmaceuticals); Anafranil Clomipramine Hydrochloride 25 mg Capsules (Basel)
    PhasePhase 1
    Registry statusCompleted